Public Research Library
Specialties:
Most Popular Reports:
- Laser Body Sculpting SmartLipo-Trends in Use
- Essure Permanent Birth Control
- Oral Contraceptives Market Evaluation
- Trends and Forecast of Dental Implant Cases
- Avastin and the AVADO Trial Survey
Newest Reports:
Market Potential of ACAPODENE® FOR ADT-Associated Osteoporosis
A Panel Discussion among Nine Physicians Specializing in the Treatment of Prostate Cancer
Price $2500
Deliverable: Transcript with key findings.
Study Objectives:
To conduct a panel discussion among urologists who specialize in the treatment of prostate cancer to examine the phase III clinical data recently released about ACAPODENE® (toremifene citrate) and evaluate how this drug might influence clinical practice if it were to receive FDA approval.
§ Understand current prevention and treatment practices regarding androgen deprivation therapy (ADT)-associated osteoporosis.
§ Examine the phase III trial results for ACAPODENE®
o Discuss the study design.
o Explore any concerns about the study.
§ Evaluate the potential clinical benefits of the drug – are the study results clinically meaningful?
§ Explore the potential use of ACAPODENE® and identify which patients might receive the medication.
§ Assess how the drug might be used relative to other medications to prevent and treat ADT-associated osteoporosis.
§ Gauge opinion about the safety of ACAPODENE®, particularly related to the risk of venous thromboembolic events (VTE).
§ Elucidate whether panelists would utilize a 60mg generic version of ACAPODENE®.
§ Uncover any other important issues surrounding ACAPODENE® and the phase III trial results.
Companies and Products Mentioned in This Report:
|
Company |
Ticker Symbol |
Products |
|
GTx |
GTXI |
ACAPODENE® (toremifene citrate) |
|
Novartis |
NVS |
ZOMETA® (zoledronic acid) |
|
Merck |
MRK |
FOSAMAX® (alendronate sodium) |
|
Amgen |
AMGN |
Denosumab |
Inclusion Criteria:
|
Inclusion Criteria
|
§ US-based § Training and board-certified in specialty § 2 - 30 years of experience post-training § From academic medical centers and community hospitals § Treats patients for osteoporosis associated with ADT given for prostate cancer § Must not have participated in the phase III trial being discussed or other trials for GTx, Inc. § Request disclosure of past and current consulting relationships § Must not have current or past professional relationship with GTx, Inc. |
Institutions represented:
|
Name of Practice |
State |
|
Urologic Oncology Practice, University of California San Francisco |
CA |
|
Dana-Farber Cancer Institute |
MA |
|
Hematology/Oncology Associates at the University Hospital in Newark |
NJ |
|
Columbia University Medical Center |
NY |
|
Urology Associates of Norwalk |
CT |
|
Private Practice |
FL |
|
Albany Urology Clinic |
GA |
|
Indiana University |
IN |
|
Central Bucks Urology |
PA |
To purchase this report or request additional information, contact:
Reports become free one year after the publication date.
 about us contact us |
 |
| © Panel Intelligence, LLC. 1999-2008. All rights reserved. A wholly owned subsidiary of MCF Corporation (NASDAQ: MERR) Privacy Policy |